Articles tagged with Cystic Fibrosis
Researchers have developed a novel therapeutic strategy for treating cystic fibrosis, restoring lung cell function to 50% of healthy levels. By using a yeast genetic model, they identified key targets that can rescue the misfolding of the deltaF508-CFTR protein, which affects nearly 90% of patients with cystic fibrosis.
Scientists at Queen's University Belfast have discovered a new molecule that can potentially prolong the life of individuals with cystic fibrosis by improving airway hydration and mucous clearance. The treatment targets the epithelial sodium channel (ENaC), preventing chronic infections and inflammation that cause progressive lung damage.
A potential drug therapy developed at the University of Pittsburgh has proven effective against bacterial biofilms and a deadly respiratory virus simultaneously. The eCAP was 50 times more effective at fighting the biofilm than traditional treatment, and reduced viable virus particles by over 150-fold in RSV-infected airway cells.
A new study from McGill University Health Centre finds that newborn screening for cystic fibrosis results in better nutrition, fewer hospitalizations, and lower rates of infection. Children diagnosed through newborn screening are also diagnosed at an earlier age and benefit more from new treatments.
Researchers have discovered that ivacaftor restores CFTR function, improves airflow, and increases the capacity and flexibility of small airways in cystic fibrosis patients. The study suggests that loss of CFTR in airway smooth muscle cells is responsible for some CF-associated symptoms.
Researchers have developed a low-cost prototype using Xbox Kinect sensors to assess respiratory function, providing more accurate measurements than traditional spirometry methods. The system enables physicians to measure and assess how a chest wall moves, which could help identify numerous respiratory problems.
A new strategic research centre will aid health professionals design bespoke physical activity and exercise plans for young people with cystic fibrosis. The centre aims to develop guidelines and recommendations for tailored activity and exercise regimes, addressing the current lack of definitive guidelines.
Recent research on cystic fibrosis lung infections highlights the ability of Pseudomonas aeruginosa to adapt and evolve in chronically infected patients. The review suggests that understanding this evolution is crucial for developing alternative treatment strategies to minimize symptoms and improve patient outcomes.
Scientists at Eindhoven University of Technology and McGill University have successfully transported the defective CFTR protein to cell walls, a crucial step towards developing a cystic fibrosis drug. The researchers discovered a naturally occurring substance called fusicoccin-A that enables this transport process.
Scientists discovered that a proton pump called ATP12A causes problems in CF lungs by increasing airway acidity. This discovery may lead to new therapies targeting this protein to halt lung disease progression. The finding builds upon earlier work using CF pigs, which showed an abnormally acidic airway liquid.
Cystic fibrosis drug ivacaftor has been shown to improve disease markers and pancreatic function in young children with a specific mutation. The study's findings suggest a potential window of opportunity for early intervention and mitigation of organ damage.
Researchers have identified alveolar macrophages as key contributors to cystic fibrosis airway inflammation, with the overabundance of XBP-1 protein mediating their inflammatory effect. This discovery bolsters the case for targeting this pathway in therapy.
A leading researcher at the Case Western Reserve University School of Nursing is developing new treatments for cystic fibrosis, a life-threatening genetic disease. The scientist will lead two studies to explore gene-modifying treatments that can minimize CF symptoms, including medications and genetic correction.
Researchers at TSRI identified a mutant protein's incorrect interactions with other cellular neighbors, which disrupted its normal function. By removing these interactions, they partially restored the protein's normal function, suggesting new therapeutic targets to treat cystic fibrosis.
Researchers at U of T discovered genetic mutations in Candida albicans that allow it to defend itself against neighboring bacteria. The fungus has evolved to ignore bacterial signals, potentially becoming a more significant threat to patients with weakened immune systems.
Researchers have made encouraging results using gene therapy to treat cystic fibrosis by inserting a healthy copy of the CFTR gene into affected cells. The approach restored chloride and fluid transport in both mouse models and human-derived cell cultures, suggesting a potential cure for the genetic disorder.
Researchers have found five genetic regions that play major roles in cystic fibrosis disease severity, which could lead to new therapies. The study analyzed over 6,000 patients and identified genetic variations associated with lung disease.
Researchers at Queen's University Belfast are developing new 'inhaled antibiotics' to manage chronic lung infection in cystic fibrosis and bronchiectasis. The €50 million project will improve patients' quality of life by reducing lung infections and flare-ups, and overcoming antibacterial resistance.
Researchers at Columbia University developed a new method for targeted drug delivery to the lung, which may provide more effective treatments for many lung diseases. By delivering small volumes of drugs directly to the pathologic site, they aim to reduce adverse effects on other organs.
Researchers found a small molecule, amphotericin B, that can substitute for a protein and restore a key cellular function related to cystic fibrosis and similar conditions. This approach shows promise as a therapeutic strategy for addressing the root cause of the disease.
Researchers found that CF microbes thrive in saliva and mucus with limited oxygen, leading to severe symptoms. Hydrogen sulfide levels in sputum samples correlated with less severe disease.
A phase 2 trial has shown that gene therapy can improve lung function in people with cystic fibrosis, with a significant benefit seen in patients who received the treatment. The technique uses inhaled molecules of DNA to deliver a normal working copy of the CFTR gene to lung cells.
A UK trial has shown significant benefits in lung function for patients with cystic fibrosis who received gene therapy. The treatment involves replacing the faulty gene responsible for the disease and was found to be safe and effective. Further research is needed to improve its effectiveness before it can be used as a clinical treatment.
A new Stanford University School of Medicine study found that cystic fibrosis is more deadly for Hispanic than non-Hispanic patients, with almost three times the mortality rate. Despite equal access to CF specialty clinics, genetic differences may be contributing to this disparity.
The five-year survival rate for Canadians with cystic fibrosis who have received a lung transplant is 67 percent, according to new research published in the Journal of Heart Lung Transplantation. Additionally, half of those who have had transplants live beyond 10 years. The study found that factors such as age at transplant and certain...
Cystic fibrosis is caused by mutations in the CFTR protein, leading to an imbalance of salt in the body. Researchers have identified two amino acids that serve as a 'gate' regulating chloride ion flow into and out of cells.
A Phase III clinical trial has shown that combined lumacaftor-ivacaftor therapy improves lung function and lowers pulmonary exacerbation rates in cystic fibrosis patients with the F508del genetic mutation. The treatment is expected to benefit around 15,000 US patients.
Women with cystic fibrosis are at risk of unplanned and mistimed pregnancies due to inadequate contraceptive use. The study found that only 49% of participants used contraception, with those having more severe CF disease being less likely to do so.
Researchers at Yale University successfully corrected the F508del mutation in the cystic fibrosis gene, a lethal genetic disorder. The novel approach uses synthetic molecules to edit the genetic defect, with minimal off-target effects.
A Europe-wide survey predicts a sharp rise in UK adults living with cystic fibrosis, expected to increase by up to 79.3% by 2025. This surge poses a significant challenge for the NHS to develop adult specialist services quickly and effectively.
Researchers at the University of Cambridge have successfully grown 'mini-lungs' using induced pluripotent stem cells derived from skin cells of patients with cystic fibrosis. These mini-lungs can be used to test potential new drugs and provide a more reliable alternative to traditional animal models.
Researchers discovered a new bodily process that explains low blood oxygen in cystic fibrosis patients with infected lungs, highlighting the importance of CFTR protein function in directing blood flow. The study suggests strategies aimed at restoring or activating the CFTR protein may improve blood oxygen levels and circulation.
The number of adults living with cystic fibrosis is expected to increase dramatically by 2025 due to improvements in treatments and care. This surge in demand highlights the need for healthcare systems to adapt and develop adult services to provide optimal care.
Researchers found that garlic extract's allicin component inhibits bacterial growth and kills certain plant pathogens, potentially offering a new treatment option for people with cystic fibrosis. The study suggests using allicin-containing remedies in combination with existing antibiotics to treat life-threatening lung infections.
A study by UNC School of Medicine researchers identified genetic pathways that play a major role in determining the severity of cystic fibrosis. The findings may lead to new personalized treatments to lessen pulmonary symptoms and increase life expectancy for people with CF.
Research found a link between altered gut bacteria and liver disease in adolescents with cystic fibrosis. The study suggests that targeting the gut microbiome may help prevent advanced liver disease.
Researchers found that cystic fibrosis mucus gets stuck inside cells, making it difficult for organs to work properly and attracting bacteria and viruses. This discovery could lead to treatments that help cells remove sticky mucus more quickly.
A recent study found that cystic fibrosis patients are at a higher risk of developing ganciclovir-resistant cytomegalovirus strains due to insufficient levels of the drug in their system. This can lead to delayed or inadequate response to treatment, highlighting the need for closer monitoring and therapeutic level adjustments.
A new study found that a cellular defense system against protein misfolding can overreact in chronic cases, worsening disease symptoms and reducing therapeutic effectiveness. Inhibiting this response with certain drugs showed promise as a treatment approach.
The ferret genome sequencing study provides insights into the effects of pandemic flu and cystic fibrosis on respiratory tissues. The analysis shows distinct responses in the trachea and lungs to different viruses, shedding light on the course of infection.
Researchers found that Canadians with cystic fibrosis are living almost 20 years longer than they did two decades ago, with the median survival age increasing to 50.9 years. The death rate declined from 1.4 deaths per year in 1990 to 0.99 deaths per year in 2012.
A new method using gold nanoparticles and light can measure the stickiness of mucus, which can help doctors monitor and treat lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease. The researchers found that this imaging method worked even when the mucus was sliding over a layer of cells.
A leading expert on respiratory medicine warns of the growing concern of antibacterial resistance in treating cystic fibrosis patients. The expert recommends further research and investigation into developing new compounds that can work against bacteria to make current antibiotics more effective.
Research found that cystic fibrosis patients have a deficiency in the immune system, specifically with HLA-DQ molecules on their cells. This deficiency affects the body's ability to fight off infections and is linked to the disease's progression.
Researchers hope a drug combination will aid in understanding why patients with cystic fibrosis struggle with exercise. Studies using sildenafil and antioxidants aim to parse the role of blood flow and endothelial dysfunction in exercise intolerance.
Scientists at Monash University developed an x-ray imaging system that allows researchers to monitor the effectiveness of treatments for cystic fibrosis. This breakthrough enables non-invasive assessment of treatment efficacy on airway surfaces, accelerating development of new treatments.
Research by University of Iowa scientists reveals that cystic fibrosis causes a primary defect in mucociliary transport, resulting in impaired detachment of mucus from airway glands. This leads to airway obstruction, difficulty breathing, and increased susceptibility to lung infection.
A new study by UNC researchers provides evidence that could help improve CF pharmacotherapies. They found that a mutant CFTR protein loses its ability to function properly when in the presence of two drugs, suggesting that drug developers should take this destabilization effect into account.
Researchers discover that mucin concentration in cystic fibrosis airway secretions contributes to decreased mucus clearance and promotes lung infection and inflammation. Meanwhile, an aptamer-based strategy delivers a specific siRNA to tumor cells and Tregs, reducing STAT3 expression and promoting anti-tumor responses.
Cystic fibrosis contributes to raised diabetes risk due to a mutated gene that inhibits insulin secretion. The mutation affects the early stage of insulin release, leading to insufficient insulin levels when demands increase.
The Phase 3 trial demonstrated positive trends in lung function, as measured by relative change in % predicted FEV1, with a 2.5% average difference between ataluren and placebo in favor of ataluren. Additionally, there were 23% fewer pulmonary exacerbations in the ataluren group compared to placebo.
Health outcomes for people with cystic fibrosis have improved dramatically following the implementation of quality improvement strategies, including patient education, nutritional support, and enhanced continuity of care. Key clinical outcomes, such as improved lung function and nutritional status, have also seen significant progress.
Researchers use computational fluid dynamics to study respiratory disorders and provide surgeons with more accurate treatment approaches. The method leads to better surgical outcomes, reduced surgeries, and improved patient recovery.
Scientists from the University of Ottawa and University of Calgary have shown that the bacterium Pseudomonas aeruginosa has genetically evolved to survive in CF-infected lungs and evade antibiotic treatments. The study provides new insights into the evolution of the pathogen, which is a major driver of cystic fibrosis mortality.
A recent study has identified MUC5B as a key protein involved in various lung-related ailments, including MRSA infections and cystic fibrosis. The protein helps control certain infections by coating airway surfaces in the nose and lungs.
Researchers are studying the molecular interactions between CFTR and SLC5A8 transport proteins in the thyroid gland, which may play a role in moving iodide into follicular lumens.
A new study published in Pediatrics found that patients with cystic fibrosis experience no rapid decline in pulmonary function or other significant health-related changes when transitioning from pediatric to adult care. The study's results contradict previous reports on negative health outcomes after transition for other chronic childh...
A £139,000 grant will investigate how cystic fibrosis patients' immune cells are infected with the B.cepacia superbug, which causes serious lung damage. The research aims to develop molecules that can help immune cells clear invading bacteria and potentially treat the condition.
Scientists at EMBL and Regensburg University identify DGKi as a potential drug target for cystic fibrosis, which regulates ENaC activity and reduces mucus thickness in patients' airways. The discovery uses large-scale screening to uncover genes not previously linked to the disease.
Researchers have identified 105 additional genetic mutations that cause cystic fibrosis, accounting for 95% of variations found in patients with the disease. This new information will provide clear answers to tens of thousands of people being screened as potential carriers and those seeking a diagnosis.